Drug intelligence / Profile preview

1C10

Development stage
Preclinical
Lead developer
Memorial Sloan Kettering Cancer Center
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravesical, Intraperitoneal, Subcutaneous
01

Overview

1C10 is a murine monoclonal antibody agonist targeting CD40, a costimulatory protein found on antigen-presenting cells such as dendritic cells. It is widely used in preclinical oncology research to stimulate antitumor immune responses. The mechanism of action for 1C10 requires the engagement of the inhibitory Fc gamma receptor IIb (FcγRIIb), which acts as a scaffold to facilitate the cross-linking and clustering of CD40 receptors necessary for downstream signaling. In models of non-muscle-invasive bladder cancer (NMIBC), intravesical administration of 1C10 has demonstrated the ability to reduce tumor burden and induce systemic, long-term antitumor immunity mediated by CD8+ T cells and conventional type 1 dendritic cells (cDC1). This murine antibody served as the foundational model for developing Fc-optimized human CD40 agonists like 2141-V11.

Other names
anti-CD40 agonist antibody 1C10anti-CD-40 agonist antibody 1C10anti-CD 40 agonist antibody 1C10rat anti-mouse CD40 antibody 1C10
02

Targets

FCGR2B (Fc gamma receptor IIB)CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on 1C10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1C10.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call